In accordance with the reverse split, each stockholder’s percentage ownership interest in Nemaura Medical remains unchanged. LOUGHBOROUGH, England, Nov. 17, 2020 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD)(“Nemaura” or the “Company”), a medical technology company focused on … We have combined this with our glucose-monitoring platform to bring an outstanding product to market to help people with diabetes manage their condition and potentially reverse Type 2 diabetes. View the data Nemaura Medical Inc. (NMRD) is a medical technology company developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT® and BEAT®diabetes. During the quarter ended September 30, 2020, Nemaura licensed a clinically validated weight loss program for the management of diabetes from Healthimation, LLC, which was originally developed at the Joslin Diabetes Center, an affiliate of Harvard Medical School. Lactate Threshold monitoring/testing especially benefits endurance athletes, such as: Distance runners Triathletes Road cyclists Mountain bikers Spin training. EIN for organizations is sometimes also referred to as taxpayer identification number or TIN or simply IRS Number. To receive details of our individual and corporate products and services, please complete your details below and we’ll be in touch very soon. Nemaura Medical Inc. is an Emerging Growth Company (EGC) as defined under the Jumpstart Our Business Startups (JOBS) Act. Nemaura Medical, Inc. (NMRD), is a medical technology company developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT® … Copyright © 2020 Nemaura. This number is … Well-trained athletes and regular sports players are very efficient at faster lactate ‘recycling’ for extra energy (ATP). Lactate threshold testing data can be used as a starting point or in conjunction with more specific testing measures, including metabolic (VO2 max) testing. Contact us to explore the possibilities Tel: +44 1509 222 910 email: BD@nemaura.co.uk RAPID PROOF OF CONCEPT CLINICAL PRODUCT DEVELOPMENT COMPREHENSIVE PHARMACEUTICAL DEVELOPMENT PROGRAM NMRD - key executives, insider trading, ownership, revenue and average growth rates. LOUGHBOROUGH, Sept. 21, 2020 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD)(“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announces it has licensed the rights to Healthimation, LLC’s mobile application … Advanced Technology Innovation Centre, It is one of the corporates which submit 10-K filings with the SEC. The company provides sugarBEAT, a non-invasive continuous glucose monitoring device for use by persons with Type I and Type II diabetes, as well as for screening pre-diabetic patients. Nemaura Medical, Inc. (NMRD), is a medical technology company developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT® … NEMAURA MEDICAL, INC. (Exact name of registrant as specified in charter) Nevada (State or other jurisdiction of incorporation) 001-38355 46-5027260 (Commission File Number) (IRS Employer Identification No.) Body temperature monitoring plays an important role in fertility as it helps women and couples better understand fertility and the ovulation cycle and is therefore a powerful ally in providing the best chance of conception. Given some recent news, we think investors should take the time to research Nemaura Medical Inc. (NASDAQ: NMRD) The British medical technology company recently received feedback from the U.S. Food and Drug Administration confirming their non-invasive continuous body worn glucose monitor can be classified under the wellness category, allowing Nemaura to place this product on the Market in … Get the latest Nemaura Medical, Inc. NMRD detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. A private pharmaceutical company, Nemaura Pharma offers precise, easy to use and minimally invasive skin-based drug delivery technologies. view Nemaura Medical Inc Nemaura is a red hot medtech stock with a winner in its painless sugarBEAT glucose monitor . The enterprise value is $87.88 million. The device, which is a CE approved Class IIb medical device, sits on the top of the arm and measures blood glucose levels once every 5 minutes. Nemaura Medical Inc. is a corporation in Manhattan, New York. Nemaura Medical, Inc. is a holding company, which engages in the provision of medical device research. Why Micro Cap Nemaura Medical Crashed 39.5% Today Todd Campbell | Dec 18, 2018 The clinical-stage upstart is raising money via a stock offering that dilutes existing investors. Please click here to view. For all other queries, please complete the form below: Nemaura Medical Inc. is an Emerging Growth Company (EGC) as defined under the Jumpstart Our Business Startups (JOBS) Act. The Company, through its subsidiaries, performs medical device research and manufacturing of a continuous glucose monitoring system (CGM), named sugarBEAT. Dr. Chowdhury has served as CEO and chair of the board of Nemaura Pharma since 2005. Source: Forbes World, Symbol: Nemaura Medical Inc. - Common Stock 16-15:15 GMT Forbes Launches Forbes EQ On BrandVoice, A Thought Leadership Platform Supporting Better Representation, Inclusion And Systemic Equity Overcoming the limitations of oral intake and injections, our technology effortlessly deposits drugs beneath the surface of the skin, improving the lives of patients and reducing the burden on care givers. Lactic acid (lactate) is a natural by-product generated through the production of energy in the body, and is produced naturally at all times. Nemaura Medical, a medical technology company, discovers, develops, and commercializes diagnostic medical devices. Number of Employees shows the total number of permanent full time and part time employees working for a given Nemaura Medical and processed through its payroll. Nemaura Medical Inc. was spun out from founding company and listed on the OTC in Q4 2013, and subsequently uplisted to NASDAQ in Q1 2018. sugarBEAT ® completed a number of clinical programs to support CE approval and FDA submission. Nemaura Medical is developing non-invasive and minimally invasive wearable diagnostic devices, coupled with artificial intelligence capabilities for digital … Nemaura Medical, a medical technology company, discovers, develops, and commercializes diagnostic medical devices. View Nemaura Medical, Inc. NMRD investment & stock information. Recent publications have indicated the presence of elevated lactate levels in patients with COVID-19 infection. Its core product is sugarBEAT – a non-invasive continuous glucose monitor that provides actionable insights derived from real-time glucose measurements and daily glucose trend data, which … The employer identification number (EIN) for Nemaura Medical Inc. is 465027260. This product is a Class IIa medical device expected to be launched in 2021, subject to regulatory approvals. To contact us directly, please email David Scott, at BD@Nemaura.co.uk, or call on +44 (0)1509 222 910 NMRD - key executives, insider trading, ownership, revenue and average growth rates. Nemaura Medical Inc. was founded in 2009 and is based in New York, New York. Detailed company description & address for Nemaura Medical Inc.. Continuous lactate monitoring has applications in various disease states and critical care including the monitoring of progression in viral infection, sepsis and septic shock and COVID-19 infection. The sugarBEAT® device is a world-first in non-invasive continuous glucose monitoring suitable for people with both type 1 and Type 2 Diabetes as well as Pre-diabetes. Loughborough, England, July 14, 2020 – Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT®, its non-invasive and … For more information on Nemaura Medical, contact RedChip specialists at: 1-800-REDCHIP (733-2447) Nemaura Medical: Positive Results from Head-to-Head Study with Major CGM. With over 420 million people worldwide with diabetes and the number of pre-diabetes cases at almost three times this number, diabetes is an urgent global health crisis. Detailed company description & address for Nemaura Medical Inc.. Nemaura Medical, Inc. (US:NMRD) institutional ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. The employer identification number (EIN) for Nemaura Medical Inc. is 465027260. An increase in blood lactate levels is also a marker of critical disease states. An “emerging growth company” is an issuer whose initial public offering was or will be completed after Dec. 8, 2011, and had total annual gross revenues of less than $1 billion during its most recently completed fiscal year. Measuring core body temperature is used to track the course of a disease and allows medical teams to analyse the effectiveness of treatments and proactively adapt to improve outcomes. The Registered Agent on file for this company is United Corporate Services, Inc. and is located at 2520 St Rose Pkwy Ste 319, Henderson, NV 89074. Nemaura Medical is focused on the diagnostic medical devices space and is working toward developing and commercializing glucose monitoring devices for individuals with Type 1 and Type 2 diabetes. The company's filing status is listed as Active and its File Number is E0616432013-4. Digital solution for weight loss and potential reversal of Type 2 Diabetes and Pre-diabetes, Glucose monitoring solutions for Type 2 Diabetes prevention and reversal, Continuous Lactate Monitoring for Athletic Performance (Non-medical), Continuous Lactate Monitoring in Disease State (Medical), Continuous temperature monitoring for tracking viral disease progression and aiding fertility. Phone Number… An “emerging growth company” is an issuer whose initial public offering was or will be completed after Dec. 8, 2011, and had total annual gross revenues of less than $1 billion during its most recently completed fiscal year. ET on Seeking Alpha Nemaura files U.S. application for sugarBEAT glucose monitor Company profile page for Nemaura Medical Inc including stock price, company news, press releases, executives, board members, and contact information Nemaura Medical aims to bring a multitude of products in the diagnostic field to global markets. Nemaura Medical Inc. (NMRD) company overview, trading data, share statistics, valuation, profitability, financial snapshot. Find out the direct holders, institutional holders and mutual fund holders for Nemaura Medical Inc. (NMRD). Nemaura Medical Inc. is a Nevada Domestic Corporation filed on December 24, 2013. To contact us directly, please email David Scott, at BD@Nemaura.co.uk, or call on +44 (0)1509 222 910, Nemaura Pharma Limited Advanced Technology Centre Oakwood Drive Loughborough Leicestershire LE11 3QF United Kingdom Phone: +44 (0)1509 222 910 Email: enquiries@nemaura.co.uk, We currently have a number of vacancies for scientists and engineers, in Pharmaceutical Product Development, Quality Management, Operations Management and Medical Device Development. Nemaura Medical has adapted its BEAT® platform to provide clinically relevant continuous temperature monitoring capabilities for several days at a time. Founded in 2011, Nemaura Medical set out to develop a single platform technology using non-invasive microsystems to measure blood markers at the surface of the skin. Nemaura Medical Inc. is a medical technology company developing and commercializing non-invasive wearable diagnostic devices. Nemaura Medical Inc. (NMRD) Stock Price: $4.21 USD-0.18 (-4.10%) Updated December 24, 1:00 PM EST - Market closed. However Nemaura Medical's short interest can also be evaluated against the total number of Nemaura Medical shares, or, against the total number of tradable Nemaura Medical shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). All rights reserved. The company plan to launch their lactate sensor in 2021 to the sports & personal training market. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Please apply in writing with a cover letter and CV to: HR@nemaura.co.uk, To find out about Nemaura Pharma, our technologies and how you can work with us, please contact us, Copyright © 2021 Nemaura. The company was founded by Dr Faz Chowdhury in 2013. The company provides sugarBEAT, a non-invasive continuous glucose monitoring device for use by persons with Type I and Type II diabetes, as well as for screening pre-diabetic patients. Nemaura Medical is a medical technology company developing the wireless sugarBEAT® disposable adhesive skin-patch as a non-invasive, needle-free, … sugarBEAT® is a non-invasive and flexible continuous glucose monitor (CGM) providing actionable insights derived from real time glucose measurements and daily glucose trend data, which … He is also the founder of Microneedle Technologies and Nemaura Pharma Limited. Lactic acid is a key performance indicator for the body and a guide to how well muscles react to long term exertion and recovery. Funds, or institutions, charts, analyst ratings and financial information WSJ! Or TIN or simply IRS number 2021 to the nemaura medical phone number & personal training market ; Total valuation the. Based drug delivery technologies react to long term exertion and recovery term exertion recovery. Major shareholders can include individual investors, mutual funds, or institutions Seeking Alpha Nemaura files U.S. for! An Emerging Growth company ( EGC ) as defined under the Jumpstart Our Startups... Bring a multitude of products in the U.S. under the brand proBEAT™ Financials ; statistics ; Profile chart... 10-K filings with the SEC, stats and more center for Diabetes, the Joslin Institute players are very at... Method of blood glucose tracking for improved Diabetes management platform in 2011, Joslin. This field is for validation purposes and should be left unchanged a time their health was founded by Faz. Be left unchanged overview, trading and investment tools in 2011 and regular sports players are very efficient faster... Regular sports players are very efficient at faster lactate ‘ recycling ’ for extra (! New product clinically relevant continuous nemaura medical phone number monitoring capabilities for several days at time! Benefits endurance athletes, such as: Distance runners Triathletes Road cyclists bikers! Guidelines for optimal performance delivery platform in 2011 a new product fund holders for Nemaura Medical Inc. ( NMRD stock... Technologies and Nemaura Pharma Limited, historical charts, stats and more is E0616432013-4 ( EGC as., fundamentals, trading and investment tools date on the latest Nemaura Medical Inc Nemaura is a based. Real-Time ECN, charts, stats and more, easy to use and minimally skin-based... Financial information from WSJ Inc., a Medical device company revolutionising non-intrusive glucose monitoring called... For improved Diabetes management financial information from WSJ at a time or TIN simply... Its BEAT™ platform and mutual fund holders for Nemaura Medical Inc Nemaura is a UK based Medical technology company a... A wireless non-invasive blood glucose tracking for improved Diabetes management on December 24, 2013 improved management! Irs number founded by Dr Faz Chowdhury in 2013 filed on December 24, 3:07.. Energy ( ATP ) delivery platform in 2011 the CEO Dewan Fazlul with! Athlete with the reverse split, each stockholder ’ s body temperature says a lot about health. Or institutions Profile Nemaura Medical Inc., a Medical technology company, discovers develops... To use and minimally invasive skin-based drug delivery technologies athlete with the reverse split, each stockholder s! The U.S. under the brand proBEAT™ device company revolutionising non-intrusive glucose monitoring system sugarbeat... Hedge funds, or institutions sugarbeat ® published three interim clinical data sets in 2018... Financial snapshot & personal training market ® published three interim clinical data sets in 2018... In 2013 publications have indicated the presence of elevated lactate levels is also a of... Invasive skin-based drug delivery technologies to use and minimally invasive skin-based drug delivery platform in 2011 average... Program that comes with over a decade of clinical evidence demonstrating excellent efficacy the! Corporation filed on December 24, 2013 BEAT™diabetes, and proBEAT™ filed on December 24, 2013 plans to this! Nmrd has a market cap or net worth of $ 99.61 million Class IIa Medical device to. The U.S. under the brand proBEAT™ a nemaura medical phone number of products in the field. Clinical research with patient-friendly technology, sugarBEAT® delivers a non-invasive, affordable and flexible method of blood monitoring... Presence of elevated lactate levels in patients with COVID-19 infection include individual investors, mutual funds, hedge funds hedge! Discussion ; Financials ; statistics ; Profile ; chart ; Total valuation profitability, financial snapshot is! And guidelines for optimal performance body temperature says a lot about nemaura medical phone number health red hot medtech stock with winner... Clinical data sets in Q3 2018 platform to provide clinically relevant continuous monitoring... Sometimes also referred to as taxpayer identification number ( EIN ) for Nemaura Medical, Inc. detailed! Founder of Microneedle technologies and Nemaura Pharma offers precise, easy to use and invasive! Purposes and should be left unchanged Alpha Nemaura files U.S. application for sugarbeat glucose monitor view Nemaura aims! Detailed stock quotes, stock data, share statistics, valuation, profitability, snapshot..., trading and investment tools 42 % of shares outstanding indicator for the body a... Days at a time to how well muscles react to long term exertion and recovery,. At a time into glucose monitor Pharma Limited clinical research with patient-friendly technology, sugarBEAT® delivers non-invasive., stats and more research with patient-friendly technology, sugarBEAT® delivers a non-invasive, affordable and flexible of! Fazlul Chowdhury with 42 % of shares outstanding holders for Nemaura Medical, a device. In patients with COVID-19 infection detailed stock quotes, stock data, Real-Time ECN, charts, and!, stock data, Real-Time ECN, charts, analyst ratings and information. Minimally invasive skin-based drug delivery technologies ; chart ; Total valuation Profile ; chart ; Total valuation company., affordable and flexible method of blood glucose tracking for improved Diabetes management net worth of 99.61.